small molecule

NIMBEX

CISATRACURIUM BESYLATE

Loss of exclusivity—loss of exclusivity

CompanyAbbVie Inc. →See this company's full patent-cliff portfolio

Drug detail

Brand name	NIMBEX
Active ingredient	CISATRACURIUM BESYLATE
Strength	EQ 2MG BASE/ML Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons
Dosage form	INJECTABLE
Route	INJECTION
Modality	Small molecule
FDA approval	December 1995
Marketing status	DISCN

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.